Vera Therapeutics - Class A (VERA) closed at $28.10 on November 13, 2026, down 3.2% from the previous close, on volume of 962,067 shares (30-day average 1,645,680).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 28, 2026 | Calendar Call Spread | 20-Nov : 18-Dec-26 35 C | 2,000 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Vera Therapeutics Earnings Call Highlights TRUTAKNA Momentum
TipRanks (Sat, 14-Nov 8:15 PM ET)
J.P. Morgan Remains a Buy on Vera Therapeutics (VERA)
TipRanks (Fri, 13-Nov 7:16 AM ET)
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 6-Nov 4:05 PM ET)
Vera Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results
Globe Newswire (Thu, 5-Nov 4:01 PM ET)
Vera Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
Globe Newswire (Mon, 2-Nov 8:00 AM ET)
Globe Newswire (Thu, 22-Oct 10:05 AM ET)
Globe Newswire (Tue, 20-Oct 8:00 AM ET)
Globe Newswire (Fri, 2-Oct 9:24 AM ET)
Globe Newswire (Tue, 15-Sep 6:30 AM ET)
Vera Therapeutics to Participate at Upcoming Investor Conferences
Globe Newswire (Tue, 1-Sep 7:30 AM ET)
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Vera Therapeutics - Class A trades on the NASDAQ stock market under the symbol VERA.
As of November 13, 2026, VERA stock price declined to $28.10 with 962,067 million shares trading.
VERA has a beta of 0.69, meaning it tends to be less sensitive to market movements. VERA has a correlation of 0.02 to the broad based SPY ETF.
VERA has a market cap of $2.02 billion. This is considered a Mid Cap stock.
Last quarter Vera Therapeutics - Class A reported $10 million in Revenue and -$1.30 earnings per share. This beat revenue expectation by $7 million and exceeded earnings estimates by $.34.
In the last 3 years, VERA traded as high as $56.05 and as low as $12.28.
The top ETF exchange traded funds that VERA belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
VERA has underperformed the market in the last year with a price return of -1.0% while the SPY ETF gained +13.4%. However, in the short term, VERA had mixed performance relative to the market. It has outperformed in the last 3 months, returning -2.7% vs -2.8% return in SPY. But in the last 2 weeks, VERA shares have been beat by the market, returning -9.3% compared to an SPY return of -0.2%.
VERA support price is $27.96 and resistance is $30.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VERA shares will trade within this expected range on the day.
